Recently added

Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver

Ros, Javier; vaghi, caterina; Garcia Rodriguez, Ariadna; Alcaraz Soler, Adriana; Baraibar, Iosune; Saoudi Gonzalez, Nadia; R Castells, Marta; Salvà, Francesc; Tabernero, Josep; Elez, Elena (MDPI, 2024-03-14)

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

Zacchi, Francesca; Semidey Raven, Maria Eugenia; Maldonado, Xavier; Perez-Lopez, Raquel; Mateo, Joaquin; Macarena, Gonzalez; Carles, Joan (Frontiers Media, 2024-03-08)

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Fasching, Peter A.; Couch, Fergus; Delaloge, Suzette; labidi-galy, sana intidhar; O’Shaughnessy, Joyce; Balmaña, Judith (Springer, 2024-04)

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Chaib, Selim; Lopez-Dominguez, Jose Alberto; Lalinde Gutiérrez, Marta; Prats, Neus; Marin Guillen, Ines; Boix Sánchez, Olga; Pérez Ramos, Sandra; Escorihuela Baez, Marta; Garcia-Garijo, Andrea; Abad, Maria; Gros, Alena; Arribas, Joaquin (Nature Portfolio, 2024-01-24)

TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

Matsubara, Nobuaki; Agarwal, Neeraj; Saad, Fred; Azad, Arun; Shore, Neal; Mateo, Joaquin (Future Medicine, 2023-10-26)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer

Scientia. Dipòsit d'Informació Digital del Departament de Salut

VHIO - Articles científics: Recent submissions

Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver ﻿

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient ﻿

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY ﻿

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2 ﻿

TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer ﻿

Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer